



1617
Attorney Docket No. LeA 33 965

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No: 10/070,963

Examiner: Jennifer M. Kim

Filed: June 28, 2002

Art Unit: 1617

Inventor(s): Erwin Bischoff, et al.,

RECEIVED

NOV 06 2003

Title: Novel Combination for the Treatment of Sexual Dysfunction.

TECH CENTER 1600/2900

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Date: October 31, 2003

Susan M. Pellegrino

Susan M. Pellegrino

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is in response to the Office Action dated October 2, 2003. In response to the restriction requirement, applicants elect 2-[2-ethoxy-5-(4-ethyl-piperazine-1-sulfonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f]-[1,2,4]-triazin-4-one as the PDE inhibitor and HMG-CoA-reductase inhibitors as the antilipemic species, as directed to claims 1, 5-10, and 12-26, for further prosecution in this application.

If there are any further fees due in connection with the filing of the present reply, please charge the fees to undersigned's Deposit Account No. 13-3372. If a fee is required for an extension of time not accounted for, such an extension is requested and the fee should also be charged to undersigned's deposit account.

Respectfully submitted,

Susan M. Pellegrino

Susan M. Pellegrino
Attorney for Applicants
Reg. No. 48,972

Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516
Telephone: (203) 812-6450
Date: October 31, 2003